These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30587457)

  • 1. De novo malignancy in heart transplant recipients: A single center experience in Japan.
    Kimura Y; Yanase M; Mochizuki H; Iwasaki K; Toda K; Matsuda S; Takenaka H; Kumai Y; Kuroda K; Nakajima S; Watanabe T; Ikura MM; Wada K; Matsumoto Y; Seguchi O; Fukushima S; Fujita T; Kobayashi J; Fukushima N
    J Cardiol; 2019 Mar; 73(3):255-261. PubMed ID: 30587457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporal Trends of De Novo Malignancy Development After Heart Transplantation.
    Youn JC; Stehlik J; Wilk AR; Cherikh W; Kim IC; Park GH; Lund LH; Eisen HJ; Kim DY; Lee SK; Choi SW; Han S; Ryu KH; Kang SM; Kobashigawa JA
    J Am Coll Cardiol; 2018 Jan; 71(1):40-49. PubMed ID: 29301626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo malignancy after lung transplantation in Japan.
    Miyazaki T; Oto T; Okumura M; Date H; Shiraishi T; Okada Y; Chida M; Kondo T; Nagayasu T
    Gen Thorac Cardiovasc Surg; 2016 Sep; 64(9):543-8. PubMed ID: 27270709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between infectious event and de novo malignancy after heart transplantation.
    Bujo C; Amiya E; Hatano M; Tsuji M; Maki H; Ishida J; Ishii S; Narita K; Endo M; Ando M; Shimada S; Kinoshita O; Ono M; Komuro I
    Heart Vessels; 2021 Apr; 36(4):499-508. PubMed ID: 33140148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of de novo malignancy and all-cause mortality among heart transplant recipients.
    Barrera FJ; Mostofsky E; Salia S; Lehman L; Liou L; Mucci L; Mittleman MA
    Int J Cardiol; 2024 Nov; 415():132455. PubMed ID: 39153512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National survey of de novo malignancy after solid organ transplantation in Japan.
    Miyazaki T; Sato S; Kondo T; Kusaka M; Gotoh M; Saiki Y; Ono M; Kokudo N; Enosawa S; Satoh S; Soeda E; Furukawa H; Kobayashi E; Nagayasu T
    Surg Today; 2018 Jun; 48(6):618-624. PubMed ID: 29380136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppression, Race, and Donor-Related Risk Factors Affect De novo Cancer Incidence Across Solid Organ Transplant Recipients.
    Bhat M; Mara K; Dierkhising R; Watt KDS
    Mayo Clin Proc; 2018 Sep; 93(9):1236-1246. PubMed ID: 30064826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De Novo Anti-HLA Antibodies After Heart Transplantation Are Associated With Adverse Events in the Long-term Follow-up of Cardiac Transplant Recipients.
    Solé-González E; Mirabet S; Brossa V; López-López L; Rivas-Lasarte M; Capellades-Olivella H; Ginel-Iglesias AJ; Martorell-Pons J; Roig E
    Transplant Proc; 2016 Nov; 48(9):3030-3032. PubMed ID: 27932139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High rates of de novo malignancy compromise post-heart transplantation survival.
    Giuliano K; Canner JK; Etchill E; Suarez-Pierre A; Choi CW; Higgins RSD; Hsu S; Sharma K; Kilic A
    J Card Surg; 2021 Apr; 36(4):1401-1410. PubMed ID: 33567114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and spectrum of metachronous malignancies in heart transplant recipients: a 11-year-experience at a German heart center.
    Strecker T; Rösch J; Weyand M; Agaimy A
    Int J Clin Exp Pathol; 2013; 6(3):411-20. PubMed ID: 23412350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and outcomes of heart transplant recipients with a pretransplant history of malignancy.
    Youn JC; Kim D; Kim KA; Kim JJ; Kim IC; Lee HS; Choi JO; Jeon ES; Nishihara K; Kransdorf EP; Chang DH; Kittleson MM; Patel JK; Ramzy D; Esmailian F; Kobashigawa JA
    Am J Transplant; 2022 Dec; 22(12):2942-2950. PubMed ID: 36050598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De Novo Malignancy After Heart, Kidney, and Liver Transplant: A Nationwide Study in Taiwan.
    Yeh CC; Khan A; Muo CH; Yang HR; Li PC; Chang CH; Chen TL; Jeng LB; Liao CC
    Exp Clin Transplant; 2020 Apr; 18(2):224-233. PubMed ID: 32133940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De novo head and neck cancer arising in solid organ transplantation recipients: The Asan Medical Center experience.
    Park MJ; Roh JL; Choi SH; Nam SY; Kim SY; Lee YS
    Auris Nasus Larynx; 2018 Aug; 45(4):838-845. PubMed ID: 29150348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of recipient age and causes of heart transplant mortality: Implications for personalization of post-transplant management-An analysis of the International Society for Heart and Lung Transplantation Registry.
    Wever-Pinzon O; Edwards LB; Taylor DO; Kfoury AG; Drakos SG; Selzman CH; Fang JC; Lund LH; Stehlik J
    J Heart Lung Transplant; 2017 Apr; 36(4):407-417. PubMed ID: 27686602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in invasive disease due to Candida species following heart and lung transplantation.
    Schaenman JM; Rosso F; Austin JM; Baron EJ; Gamberg P; Miller J; Oyer PE; Robbins RC; Montoya JG
    Transpl Infect Dis; 2009 Apr; 11(2):112-21. PubMed ID: 19254327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low incidence of malignancy in heart-transplant recipients in Taiwan: an update and comparison with kidney-transplant recipients.
    Hsu RB; Chang CI; Tsai MK; Lee PH; Chou NK; Chi NH; Wang SS; Chu SH
    Eur J Cardiothorac Surg; 2010 May; 37(5):1117-21. PubMed ID: 20045346
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Manzia TM; Angelico R; Gazia C; Lenci I; Milana M; Ademoyero OT; Pedini D; Toti L; Spada M; Tisone G; Baiocchi L
    World J Gastroenterol; 2019 Sep; 25(35):5356-5375. PubMed ID: 31558879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-transplant malignancy in liver transplantation: a single center experience.
    Hsiao CY; Lee PH; Ho CM; Wu YM; Ho MC; Hu RH
    Medicine (Baltimore); 2014 Dec; 93(28):e310. PubMed ID: 25526480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De novo DQ donor-specific antibodies are associated with worse outcomes compared to non-DQ de novo donor-specific antibodies following heart transplantation.
    Cole RT; Gandhi J; Bray RA; Gebel HM; Morris A; McCue A; Yin M; Laskar SR; Book W; Jokhadar M; Smith A; Nguyen D; Vega JD; Gupta D
    Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28181305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De Novo Malignancies After Transplantation: Risk and Surveillance Strategies.
    Doycheva I; Amer S; Watt KD
    Med Clin North Am; 2016 May; 100(3):551-67. PubMed ID: 27095645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.